Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level

被引：0
|
作者：
N. M. Atallah
M. Alsaleem
M. S. Toss
N. P. Mongan
E. Rakha
机构：
[1] the University of Nottingham and Nottingham University Hospitals NHS Trust,Division of Cancer and Stem Cells, School of Medicine
[2] Menoufia University,Department of Pathology, Faculty of Medicine
[3] Qassim University,Unit of Scientific Research, Applied College
[4] Sheffield Teaching Hospitals NHS Foundation Trust,Histopathology Department, Royal Hallamshire Hospital
[5] University of Nottingham,School of Veterinary Medicine and Sciences
[6] Weill Cornell Medicine,Department of Pharmacology
来源：
British Journal of Cancer | 2023年 / 129卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1692 / 1705
页数：13
相关论文
共 50 条
  • [31] In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment
    Lien, Huang-Chun
    Lo, Chiao
    Lee, Yi-Hsuang
    Lin, Po-Hang
    Wang, Ming-Yang
    Kuo, Wen-Hung
    Tsai, Li-Wei
    Lu, Yen-Shen
    Hu, Hsiang-Wei
    Li, Yu-Chia
    Huang, Chiun-Sheng
    BREAST CANCER RESEARCH, 2024, 26 (01)
  • [32] Quantitative digital imaging analysis of HER2 immunohistochemistry predicts the response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma
    Aidan C. Li
    Jing Zhao
    Chao Zhao
    Zhongliang Ma
    Ramon Hartage
    Yunxiang Zhang
    Xiaoxian Li
    Anil V. Parwani
    Breast Cancer Research and Treatment, 2020, 180 : 321 - 329
  • [33] Quantitative digital imaging analysis of HER2 immunohistochemistry predicts the response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma
    Li, Aidan C.
    Zhao, Jing
    Zhao, Chao
    Ma, Zhongliang
    Hartage, Ramon
    Zhang, Yunxiang
    Li, Xiaoxian
    Parwani, Anil, V
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 321 - 329
  • [34] HER2 equivocal breast cancer and neoadjuvant therapy: Is response similar to HER2-positive or HER2-negative tumors?
    Landmann, Alessandra
    Farrugia, Daniel J.
    Diego, Emilia
    Bonaventura, Marguerite
    Soran, Atilla
    Johnson, Ronald
    Dabbs, David J.
    Clark, Beth
    Brufsky, Adam
    Davidson, Nancy E.
    Lembersky, Barry C.
    Jankowitz, Rachel Catherine
    Puhalla, Shannon
    Ahrendt, Gretchen M.
    McAuliffe, Priscilla F.
    Bhargava, Rohit
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [35] LEVEL OF HER2/NEU GENE (HER2) AMPLIFICATION IN PRIMARY AND METASTATIC SITES IN HER2-POSITIVE METASTATIC BREAST CANCER AND RESPONSE TO TRASTUZUMAB(T)-BASED THERAPY
    Gullo, G.
    Bettio, D.
    Zuradelli, M.
    Giordano, L.
    Masci, G.
    Bareggi, C.
    Salvini, P.
    Venci, A.
    Santoro, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 101 - 101
  • [36] Stability of HER2 Expression in Residual Breast Cancer Following Neoadjuvant Anti-HER2 Therapy.
    Mir, Mariam O.
    Sahoo, Sunati
    Fang, Yisheng
    Peng, Yan
    Hwang, Helena
    Czapla, Agata
    Koduru, Prasad
    Sarode, Venetia
    MODERN PATHOLOGY, 2018, 31 : 91 - 91
  • [37] HER2 testing and its predictive utility in anti-HER2 breast cancer therapy
    Advani, Pooja P.
    Crozier, Jennifer A.
    Perez, Edith A.
    BIOMARKERS IN MEDICINE, 2015, 9 (01) : 35 - 49
  • [38] De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer
    Madrid-Paredes, Adela
    Canadas-Garre, Marisa
    Sanchez-Pozo, Antonio
    Angel Calleja-Hernandez, Miguel
    PHARMACOGENOMICS, 2015, 16 (12) : 1411 - 1426
  • [39] Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer
    Takahito Masuda
    Hiroshi Fujimoto
    Ryotaro Teranaka
    Masayuki Kuroda
    Yasuyuki Aoyagi
    Takeshi Nagashima
    Takafumi Sangai
    Mamoru Takada
    Ayako Nakagawa
    Yoshitaka Kubota
    Koutaro Yokote
    Masayuki Ohtsuka
    Breast Cancer Research and Treatment, 2020, 180 : 625 - 634
  • [40] Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism
    Hans F Schoellhammer
    Felicia Hsu
    Courtney Vito
    Peiguo Chu
    Jinha Park
    James Waisman
    Joseph Kim
    BMC Cancer, 14
12345